TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer

Trial Profile

TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Sorafenib (Primary) ; Doxorubicin
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TACE-2
  • Most Recent Events

    • 07 Jun 2016 Status changed from recruiting to discontinued as reported by results presented at the 52nd Annual meeting of the American Society of Clinical Oncology.
    • 25 Feb 2016 Planned End Date changed from 31 Aug 2016 to 7 Dec 2015 as reported by united Kingdom clinical Research Network.
    • 16 Feb 2016 Planned End Date changed from 7 Dec 2015 to 31 Aug 2016 as per ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top